Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study

2018238 citationsJournal Articlehybrid Open Access

Authors

Kenji Kabashima · Kyoto University

Masutaka Furue · Kyushu University

Jon M. Hanifin · Oregon Health & Science University

Grażyna Pulka · Jagiellonian University

Andreas Wollenberg · Ludwig-Maximilians-Universität München

Ryszard Galus · Medical University of Warsaw

Takafumi Etoh ·

Abstract

Nemolizumab for up to 64 weeks was efficacious and overall well tolerated in patients with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy.

Topics & Keywords

Dermatology and Skin Diseases Allergic Rhinitis and Sensitization Food Allergy and Anaphylaxis Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Allergy and Clinical Immunology

Volume 142, Issue 4, pp. 1121-1130.e7

DOI: 10.1016/j.jaci.2018.03.018

Field-Weighted Citation Impact: 37.09